Glenmark to market generic of GSK’s Seretide Accuhaler with Celon
Glenmark Pharmaceuticals Europe Ltd (Glenmark) has announced that it has entered into a strategic development and licensing agreement with Poland based Celon... Read More
+91-98 455 710 46 | info@nckpharma.com
Sign In
|Sign Up
Please sign in first
Not a member?
Please simply create an account before buying/booking any courses.
Create an account for free!
- Home
- About Us
- NCK services
- Course List
- Admission
- Course Quick Glance
- Features of Online Courses
- Course Catalogue
- Course Application form
- Admission Notification & Special Offers
- Frequently asked question related to KPE courses
- Prospect Identification Process
- Final Examination Registration
- How to change / reset password?
- Course Upgrade
- Verify Course Certificate
- Request for Course Completion Certificate
- Knowledge Base
- Contact
Tag
Seretide Accuhaler
Our Popular Courses
Recent Articles
- Pharma Case Study: Merck’s $11.5B acquisition of Acceleron
- Sanofi Bangladesh Limited’s majority stake is acquired by Beximco Pharma, Bangladesh
- What are the difference between Wholesaler and Specialty Pharmacy?
- What is Scale-Up and Post Approval Changes (SUPAC) report?
- What is the meaning of scale up in pharmaceutical industry?
- RIL arm acquires stake in Strand Life Sciences for Rs. 393 crore
- DRL enters agreement to sell its rights to anti-cancer agent E7777 to Citius Pharma
- Takeda and Frazier announced a collaboration to launch HilleVax, Inc, a biopharmaceutical company, to develop and commercialize Takeda’s norovirus vaccine candidate
- Nucala received USFDA approval to treat chronic rhinosinusitis with nasal polyps
- Case Insight: Piramal Pharma’s acquisition of Hemmo Pharmaceuticals
- FDC launches Favipiravir oral suspension to treat mild to moderate cases of COVID-19
- Rossari Biotech to acquire Tristar Intermediates
- Sun Pharma launches a special initiative ‘Sunkalp’ for the welfare of doctors
- Case Insight – ANI Pharmaceuticals acquisition of Novitium Pharma
- Astrazeneca has been given the all-clear to buy rare disease drug maker Alexion in a blockbuster £28billion deal.
- Kintor Pharmaceutical collaborates with Fosun Pharma Development to Commercialise Proxalutamide
- Codexis’s CodeEvolver platform technology transfer deal with Novartis
- Lupin’s Somerset plant received US FDA warning letter for
- What is Cytokine Storm?
- FDA Grants Accelerated Approval for Alzheimer’s drug Aduhelm